Trump’s triple-digit tariff essentially cuts off most trade with China, says economist

Trump’s triple-digit tariff essentially cuts off most trade with China, says economist


U.S. President Donald Trump attends a cabinet meeting at the White House in Washington, D.C., U.S., April 10, 2025.

Nathan Howard | Reuters

President Donald Trump’s tariff increase on imports from China would basically end most trade between that country and the U.S., according to economist Erica York.

“It depends on how narrowly the tariff is applied or how broadly it’s applied, but generally if you get north of a triple-digit tariff, you are cutting off most trade,” the vice president of federal tax policy at the Tax Foundation’s Center for Federal Tax Policy said on CNBC’s “The Exchange” on Thursday. “There may still be some things without any substitutes that companies just have to foot the bill, but for the most part, that cuts it off.”

Her remarks came amid the market wiping out some of its monster gains seen on Wednesday. The market accelerated declines on Thursday once a White House official confirmed to CNBC that the U.S. tariff rate on Chinese goods now stands at 145%. That total includes the recent hike to 125% from 84% that Trump announced Wednesday as well as a 20% fentanyl-related duty that the president had previously put into effect.

York stressed that the market isn’t in the clear just yet, saying “it’s not like the threat went away entirely,” with no clarity expected until July when the reprieve is scheduled to end.

On Wednesday, Trump announced that he’s temporarily reducing the tariff rates on imports from most countries, except China, to 10% for 90 days. In a Cabinet meeting Thursday, the president declined to rule out the possibility of extending the 90-day tariff reprieve.

Taking into account the China tariffs, the baseline 10% levies still in place and other sector tariffs, Trump has still taken the country into its most protectionist stance in decades, even with the pause.

“It’ll take the average tariff rate still to highs that we haven’t seen since the 1940s, so this is major,” the economist added. “It’s huge cost increases. It’s an economic hit. It’s clearly not setting us on a very good path.”

The Tax Foundation estimates that all of the new Trump tariffs will lead to an increase in federal tax revenues of $171.6 billion for this year. That would make Trump’s tariffs the biggest tax increase since 1993, more than the hikes under both former presidents George H.W. Bush and Barack Obama, the institution revealed.

China has said it won’t flinch if trade dynamics were to escalate into a trade war. Just hours prior to Trump’s tariff pause announcement, China raised its retaliatory levies on U.S. imports to 84% from 34%, which went into effect Thursday.



Source

CNBC’s The China Connection newsletter: China’s K-visa plans spark worries of a talent flood
World

CNBC’s The China Connection newsletter: China’s K-visa plans spark worries of a talent flood

This report is from this week’s CNBC’s The China Connection newsletter, which brings you insights and analysis on what’s driving the world’s second-largest economy. You can subscribe here. The big story Immigration anxieties and a challenging job market have sparked an online backlash over China’s latest attempt at attracting global talent — a new visa program […]

Read More
India holds rates steady at 5.5% in line with forecast as central bank assesses earlier cuts
World

India holds rates steady at 5.5% in line with forecast as central bank assesses earlier cuts

India’s central bank kept its policy rate unchanged at 5.5% Wednesday, in line with the expectations of economists polled by Reuters, as it assessed the impact of earlier cuts. Inflation moderated significantly in the first quarter, but growth could decelerate in the second half of the financial year due to global trade uncertainties, said Sanjay […]

Read More
CNBC’s UK Exchange newsletter: AstraZeneca gets a shot on Wall Street
World

CNBC’s UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

This report is from this week’s CNBC’s UK Exchange newsletter. Like what you see? You can subscribe here. The dispatch There is an old British saying about buses: you wait ages for one and then two arrive at once. Pharmaceuticals analysts experienced something similar on Monday as the big two U.K. drugmakers — GSK and AstraZeneca — […]

Read More